Janssen launches new accelerator for digital corporations targeted on predictive diagnostics and precision therapy

Janssen launches new accelerator for digital companies focused on predictive diagnostics and precision treatment

Janssen, Johnson & Johnson’s pharma subsidiary, is trying to the digital well being startup area for brand new concepts on predictive diagnostics and precision therapy. The corporate has launched a brand new nine-month startup accelerator targeted on the Europe, Center East and Africa (EMEA) area.

Startups may have till Sept 27 to use to the accelerator and should focus their pitch round methods to enhance therapy initiation with predictive diagnostic fashions and options or creating precision-treatment administration instruments that use biomarkers and contextual knowledge, in accordance with the group’s internet web page. The trouble is supported by iPEPS, a French mind well being incubator and EIT Well being, an EU innovation community. 

This system is providing the chosen startups 9 months of help and mentorship with members of Janssen and iPEPS. Startups will even have entry to iPEPS Residing Lab, that are housed inside the Pitié-Salpêtrière hospital system. This system was additionally developed to assist startups join with numerous networks past the sponsors together with traders and material specialists.  

HIMSS20 Digital

Study on-demand, earn credit score, discover merchandise and options. Get Began >>


The pharma business has continued to set its sights on the digital well being world. A number of corporations are teaming up with startups or traditionally digital corporations to conduct analysis, provide companion apps, or discover the world of digital therapeutics. We’ve even seen executives at J&J talk about the alternatives within the area. 

“Very quickly, digital instruments will develop into a part of scientific trials in many alternative illness areas [because] the price of scientific trials is so excessive,” Dr. Paul Stoffels, vice chairman of the manager committee and chief scientific officer at J&J, stated on the American Coronary heart Affiliation Scientific Periods final 12 months. “If it’s important to have 300,000 individuals in an outcomes scientific trial, the associated fee was a whole bunch of thousands and thousands if not billions of {dollars}. Now it’s doable, and it in a short time will change your complete discipline. Digital recruitment and inclusion, individuals having the ability to be handled at dwelling, digital consultations – that may all assist to do quicker and less complicated trials.”

Pharma can be notoriously properly funded. This curiosity in predictive diagnostics and precision remedies could possibly be an indicator of the subsequent subjects of curiosity for the business. 


Janssen has been concerned within the digital area for some time. The truth is, final 12 months the corporate kicked off a very decentralize digital scientific research, referred to as CHIEF-HF. On the time of the announcement, the pharma firm stated that the trial will embody no in-person visits and rely solely on digital communication.

Johnson & Johnson has additionally teamed up with Apple to launch a brand new digital well being research set to discover the affect of Apple’s gadgets – and a study-specific engagement program on cardiovascular outcomes among the many Medicare inhabitants. 

Supply hyperlink

Be the first to comment

Leave a Reply